Case report and literature review of BRAF‐V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. (12th January 2022) - Nussbaum, Penelope E.
Abstract: What is known and objective: The BRAF ‐ V600E genetic mutation offers a potential targeted therapy for the treatment of papillary craniopharyngiomas. Case summary: A 35‐year‐old man underwent a craniotomy and subtotal resection of a large BRAF ‐ V600E ‐positive papillary craniopharyngioma before referral to our institution. Our treatment included the BRAF‐V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide (2 mg/day). The residual tumour decreased in size by 95% over 21 months without negative side effects. What is new and conclusion: We reviewed the literature on BRAF‐V600E inhibition as a non‐invasive method of treating papillary craniopharyngiomas harbouring the BRAF ‐ V600E mutation.